Fig. 4: Evidence of target engagement. | Nature Communications

Fig. 4: Evidence of target engagement.

From: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Fig. 4

Reductions in CDK1/2/3 and pPolII levels in paired tumor biopsy samples demonstrates target engagement and proof of mechanism. Images are representative of two technical replicates from paired biopsies from a single patient. See Supplementary Table 11 for quantification and additional data from a further 5 patient paired biopsies. CDK cyclin-dependent kinase, OD once daily, pCDK phosphorylated cyclin-dependent kinase, pPolII phosphorylated RNA polymerase II.

Back to article page